_PRIVATE_LIMITED.webp)
Rekvina Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-05-2024
- Paid Up Capital ₹ 5.00 M
as on 15-05-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.50 M
as on 15-05-2024
- Revenue -64.75%
(FY 2020)
- Profit -1256.63%
(FY 2020)
- Ebitda -1226.27%
(FY 2020)
- Net Worth -2084.19%
(FY 2020)
- Total Assets -21.36%
(FY 2020)
About Rekvina Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹7.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Surbhit Shah and Mukesh Shah serve as directors at the Company.
- CIN/LLPIN
U24230MH2007PTC170589
- Company No.
170589
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2007
- Date of AGM
11 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Rekvina Pharmaceuticals (India) Private Limited offer?
Rekvina Pharmaceuticals (India) Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication, Herbal Piles Medicine, Herbal Piles Capsules and Tablets, Nutraceuticals, Pancreatin Tablets, Common Disease Medicines, Antihistamines.
Who are the key members and board of directors at Rekvina Pharmaceuticals (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surbhit Shah  | Director | 04-May-2007 | Current |
| Mukesh Shah | Director | 04-May-2007 | Current |
Financial Performance of Rekvina Pharmaceuticals (India).
Rekvina Pharmaceuticals (India) Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 64.75% decrease. The company also saw a substantial fall in profitability, with a 1256.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 2084.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rekvina Pharmaceuticals (India)?
In 2020, Rekvina Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Varshaben Mukeshbhai Shah FoundationActive 7 years 11 months
Surbhit Shah and Mukesh Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 18 May 2010 | ₹7.50 M | Satisfied |
How Many Employees Work at Rekvina Pharmaceuticals (India)?
Rekvina Pharmaceuticals (India) has a workforce of 47 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rekvina Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rekvina Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
